Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Researchers at Johns Hopkins and their collaborators conducted an open-label phase I clinical trial of a new treatment, in which a viral vector expressing the gene for sFLT01, a protein that ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Nutritional therapy can aid treatment in the early stages of dry macular degeneration ... Future access to gene chips could lead to more accurate AMD and glaucoma diagnosis and treatment.

National Eye Institute. Age-Related Macular Degeneration. American Academy of Ophthalmology. Eye health information for adults over 65. National Eye Institute. AREDS/AREDS2 Clinical Trials. Macular ...

BENGALURU: Bengaluru-based Narayana Nethralaya is developing gene therapy solutions that could drastically reduce the cost of ...

Aug. 24, 2022 — Researchers have developed a new gene therapy approach that shows promise for treating the dry form of Age Related Macular Degeneration (AMD) -- a progressive eye disease that ...

Last year, it claimed a $370 million licensing deal with AbbVie for an AAV8 gene therapy candidate RGX-314 for wet age-related macular degeneration (AMD).

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.